Merck Raises Revenue Forecast on New Drug Sales but Lowers Profit Outlook Due to Acquisition Charges
Merck increased its revenue expectations driven by growth in new drug sales but reduced profit guidance because of costs related to its acquisition of Terns Pharmaceuticals.
Merck announced an upward revision to its revenue forecast, citing strong sales growth in its new drug portfolio. However, the company simultaneously lowered its profit guidance. The profit outlook was adjusted downward due to a charge associated with Merck's recent acquisition of biotech firm Terns Pharmaceuticals. This development was reported on August 4, 2026.
Sources
CNBC — Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal chargesTHE QUESTIONS THIS EVENT LEAVES BEHIND